Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1988 Oct;58(4):497-9.
doi: 10.1038/bjc.1988.248.

Tamoxifen, serum lipoproteins and cardiovascular risk

P F Bruning  1 , J M Bonfrer, A A Hart, M de Jong-Bakker, D Linders, J van Loon, W J Nooyen
Affiliations
Free PMC article

Tamoxifen, serum lipoproteins and cardiovascular risk

P F Bruning et al. Br J Cancer. 1988 Oct.
Free PMC article

Abstract

The influence of tamoxifen on plasma lipids and lipoproteins was monitored in 46 postmenopausal and 8 premenopausal women treated for advanced breast cancer up till 6 months. Total cholesterol (total-C) did not significantly change. However, high density lipoprotein cholesterol (HDL-C) and the HDL-C/total-C ratio rose significantly. Low density lipoprotein cholesterol was significantly decreased. Triglycerides and free fatty acids did not change markedly. The concomitant rise of sex hormone binding globulin and thyroxine binding globulin indicates that the increase of HDL-C with prolonged use of tamoxifen is compatible with an intrinsic oestrogenic effect of tamoxifen on the liver. The increased HDL-C/total-C ratio lends no support to the concern that long-term administration of this anti-oestrogenic drug might lead to an increased cardiovascular risk.

PubMed Disclaimer

References

    1. Clin Chem. 1972 Jun;18(6):499-502 - PubMed
    1. J Lipid Res. 1970 Nov;11(6):583-95 - PubMed
    1. Circulation. 1987 Jun;75(6):1340A-1362A - PubMed
    1. Am J Cardiol. 1987 Jun 1;59(15):1271-6 - PubMed
    1. Clin Chem. 1977 May;23(5):882-4 - PubMed

Publication types